Advanced Proteome Therapeutics Corporation

DB:0E81 Stock Report

Market Cap: €279.9k

Advanced Proteome Therapeutics Valuation

Is 0E81 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0E81 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0E81's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0E81's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0E81?

Key metric: As 0E81 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0E81. This is calculated by dividing 0E81's market cap by their current book value.
What is 0E81's PB Ratio?
PB Ratio-13.9x
Book-US$21.74k
Market CapUS$302.33k

Price to Book Ratio vs Peers

How does 0E81's PB Ratio compare to its peers?

The above table shows the PB ratio for 0E81 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average15.2x
T5O bioXXmed
13.2xn/a€1.4m
CNW co.don
1xn/a€6.5m
MDG1 Medigene
0.9x11.0%€17.4m
VSC 4SC
45.8xn/a€50.2m
0E81 Advanced Proteome Therapeutics
n/an/a€411.3k

Price-To-Book vs Peers: 0E81 has negative equity and a Price-To-Book Ratio (-13.9x) compared to the peer average (0.7x).


Price to Book Ratio vs Industry

How does 0E81's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
0E81 is unprofitableIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0E81 has negative equity and a Price-To-Book Ratio (-13.9x) compared to the European Biotechs industry average (2.5x).


Price to Book Ratio vs Fair Ratio

What is 0E81's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0E81 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-13.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0E81's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies